353 related articles for article (PubMed ID: 14529478)
1. From discovery to the coming generation of histone deacetylase inhibitors.
Yoshida M; Matsuyama A; Komatsu Y; Nishino N
Curr Med Chem; 2003 Nov; 10(22):2351-8. PubMed ID: 14529478
[TBL] [Abstract][Full Text] [Related]
2. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase as a new target for cancer chemotherapy.
Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
Marson CM
Anticancer Agents Med Chem; 2009 Jul; 9(6):661-92. PubMed ID: 19601748
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
7. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors from microorganisms: the Astellas experience.
Masuoka Y; Shindoh N; Inamura N
Prog Drug Res; 2008; 66():335, 337-59. PubMed ID: 18416310
[TBL] [Abstract][Full Text] [Related]
9. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.
Zhu WG; Otterson GA
Curr Med Chem Anticancer Agents; 2003 May; 3(3):187-99. PubMed ID: 12769777
[TBL] [Abstract][Full Text] [Related]
10. The structure and function of histone deacetylases: the target for anti-cancer therapy.
Zhang Y; Fang H; Jiao J; Xu W
Curr Med Chem; 2008; 15(27):2840-9. PubMed ID: 18991639
[TBL] [Abstract][Full Text] [Related]
11. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
12. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
15. The changing face of HDAC inhibitor depsipeptide.
Zhou W; Zhu WG
Curr Cancer Drug Targets; 2009 Feb; 9(1):91-100. PubMed ID: 19200053
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057
[TBL] [Abstract][Full Text] [Related]
18. The potential of histone deacetylase inhibitors in lung cancer.
Aparicio A
Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: gathering pace.
Carey N; La Thangue NB
Curr Opin Pharmacol; 2006 Aug; 6(4):369-75. PubMed ID: 16781195
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
Kollar J; Frecer V
Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]